It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.08.23295233;](https://doi.org/10.1101/2023.09.08.23295233) this version posted September 8, 2023. The copyright holder for this preprint

#### **Phenome-wide association study of ovarian cancer identifies common comorbidities and reveals**

#### **shared genetics with complex diseases and biomarkers**

Anwar Mulugeta<sup>1,2&3\*</sup>, Amanda L Lumsden<sup>1&2</sup>, Iqbal Madakkatel<sup>1&2</sup>, David Stacey<sup>1&2</sup>, S.Hong Lee<sup>1,2&4</sup>, Johanna Mäenpää<sup>5&6</sup>, Martin K. Oehler<sup>7&8</sup>, Elina Hyppönen<sup>1&2</sup>

<sup>1</sup> Australian Centre for Precision Health, Unit of Clinical and Health Sciences, University of South Australia, Adelaide, Australia

2 South Australian Health and Medical Research Institute, Adelaide, Australia

<sup>3</sup>Department of Pharmacology and Clinical Pharmacy, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia

4 UniSA Allied Health & Human Performance, University of South Australia, Adelaide, SA, Australia <sup>5</sup>Faculty of Medicine and Medical Technology, Tampere University, Tampere, Finland

6 Cancer Centre, Tampere University and University Hospital, Tampere, Finland

7 Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia 8 Adelaide Medical School, Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia

**Short title**: MR-PheWAS of ovarian cancer

**Funding**: This research was funded by Medical Research Future Fund of Australia (MRF2007431).

**Competing interests**: The authors declare that they have no competing interests.

**\*Corresponding author**: Dr Anwar Mulugeta Australian Centre for Precision Health, c/o SAHMRI, University of South Australia, Adelaide, Australia, GPO Box 2471, Adelaide SA 5001. Email: anwarmulugeta.gebremichael@unisa.edu.au

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

### 1 **Abstract**

2 **Background**: Ovarian cancer (OC) is commonly diagnosed among older women who have 3 comorbidities. This hypothesis-free phenome-wide association study (PheWAS) aimed to identify 4 comorbidities associated with OC, as well as traits that share a genetic architecture with OC. 5 **Methods**: We used data from 181,203 white British female UK Biobank participants and analysed 6 OC and OC subtype-specific genetic risk scores (OC-GRS) for an association with 889 diseases and 7 43 other traits. We conducted PheWAS and colocalisation analyses for individual variants to identify 8 evidence for shared genetic architecture. 9 **Results**: The OC-GRS was associated with 10 diseases, and the clear cell OC-GRS was associated 10 with five diseases at the FDR threshold ( $p = 5.6 \times 10^{-4}$ ). Mendelian randomisaiton analysis (MR) 11 provided robust evidence for the association of OC with higher risk of "secondary malignant 12 neoplasm of digestive systems" (OR 1.64, 95% CI 1.33, 2.02), "ascites" (1.48, 95% CI 1.17, 1.86), 13 "chronic airway obstruction" (1.17, 95% CI 1.07, 1.29), and "abnormal findings on examination of 14 the lung" (1.51, 95% CI 1.22, 1.87). Analyses of lung spirometry measures provided further support 15 for compromised respiratory function. PheWAS on individual OC variants identified five genetic 16 variants associated with other diseases, and seven variants associated with biomarkers (all,  $p \le 4.5 \times 10^{-16}$ 17 <sup>8</sup>). Colocalisation analysis identified rs4449583 as the shared causal variant for OC and seborrheic 18 keratosis.

19 **Conclusions**: OC is associated with digestive and respiratory comorbidities. Several variants 20 affecting OC risk were associated with other diseases and biomarkers, with this study identifying a 21 novel genetic locus shared between OC and skin conditions.

- **Keywords:** Ovarian cancer, comorbidities, *TERT*, PheWAS, UK Biobank 23
- 24

## 25 **1. Introduction**



51

#### 52 **2. Methods**

## 53 **2.1.Study population**

54 UK Biobank is a prospective cohort study of half a million participants with rich phenotype and 55 genotype data collected across 22 centres in England, Scotland, and Wales. The baseline assessment 56 was conducted between 2006 and 2010 when the participants were aged between 37 to 73 years.<sup>11</sup> A 57 wide range of data was collected, including sociodemographic information, lifestyle factors, physical 58 measures, blood and urine samples for biomarker and genetic profiling, with continuing updates 59 through follow-up assessments and linkage with electronic health records and death registrations.<sup>11</sup> 60 For the primary analyses in this study, we restricted the sample to 181,203 female participants who 61 were of white British ancestry and were not genetically related (Figure S1) and included male 62 participants in sensitivity analyses ( $n = 156,220$ ). The study was conducted under UK Biobank 63 application number 89630. UK Biobank obtained informed consent from all participants to collect and 64 use linked data for future research use, and the UK Biobank study has ethical approval from the 65 National Information Governance Board for Health and Social Care and Northwest Multicenter 66 Research Ethics Committee (11/NW/0382).

67

#### 68 **2.2.Disease outcomes and biomarkers**

69 We used International Classification of Diseases (ICD version 9 and 10) codes from hospital episode 70 statistics and death registrations to identify disease outcomes (Supplementary methods). We mapped 71 ICD-9/10 codes to phecodes, which are composite groupings reflecting clinically relevant disease outcomes.12 72 We defined individuals with the phecode-of-interest as cases, and those without the 73 phecode-of-interest, or any other phecodes from the same disease category as controls 74 (Supplementary methods).<sup>12, 13</sup> We included all phecodes with at least 200 cases in our analyses,<sup>14</sup> 75 resulting in 889 phecodes from 18 disease categories (Table S1).

76 We also included 30 serum and four urine biomarkers, which are commonly used for the diagnosis

77 and monitoring of chronic diseases, as outcome measures (Supplementary methods). Additional

78 analyses were conducted against selected physiological characteristics (namely body mass index

- 79 (BMI), body fat percentage (BFP), basal metabolic rate (BMR), blood pressures, and measures of
- 80 lung function (spirometry) due to their known associations with comorbidity risks. The spirometry
- 81 measures included forced expiratory volume in 1-second (FEV1), forced vital capacity (FVC),
- 82 FEV1/FVC ratio, and peak expiratory flow (PEF).

### 83 **2.3.Genetic variants and genetic risk score**

- 84 We selected 35 genetic variants associated with OC from previous genome-wide association studies
- 85 (GWAS), including the 12 novel variants identified in the most recent GWAS  $15$  and 23 variants

86 identified in earlier GWASs (minor allele frequency  $>1.4\%$ , Table S2, Figure S2).<sup>16-23</sup> We

87 constructed the genetic risk score (GRS) using 31 genetic variants after excluding one variant that had

88 no proxy at  $r^2 \ge 0.8$  (rs555025179), and three variants (rs12131772, rs4691139, and rs12938171) that

89 were not replicated in the recent GWAS,<sup>15</sup> which we extracted from the imputed genotype UK

- 90 Biobank data  $^{24}$  (Table S2). The GRS was constructed for each individual by summing the weighted
- 91 number of OC risk-associated variants, with the weight taken from the recent OC GWAS.<sup>15</sup> We also
- 92 constructed risk scores for each OC subtype (Supplementary methods).

#### 93 **2.4.Statistical analyses**

94 We conducted phenome-wide analyses using R-package PheWAS  $^{25}$  which allowed us to fit logistic

95 regression (889 disease outcomes) or linear regression (43 biomarkers/physiological characteristics)

96 against the OC GRS with all models adjusted for age, assessment centre, type of genotyping array,

97 birth location, and 40 principal components (Figure S2). We repeated the phenome-wide analyses for

98 each OC subtype GRS to identify subtype-specific disease associations, and further, conducted the

99 analyses in male participants to understand whether the OC – disease associations involve non-sex-

100 specific mechanistic pathways.



126 Statistical analyses were performed using STATA SE version 17.1, R version 4.2.1 and PLINK2.<sup>32</sup>

#### 127 **3. Results**

- 128 We included up to 181,203 female white British participants in the primary analyses, of whom 1,863
- 129 (1.3%) had been diagnosed with OC (Table 1). The prevalence of OC was higher among participants
- 130 who were older, obese, never drinkers of alcohol, and those with poor general health status at the
- 131 baseline (for all, prevalence ≥1.2%, and p ≤0.03). The OC risk GRS was normally distributed and
- 132 associated with OC as expected, with stronger association in the highest compared to the lowest
- 133 genetic risk group (F-statistics =23.7, p =4.4  $\times$  10<sup>-16</sup>, Figure S3). No associations were found between
- 134 the risk scores and potential confounders after correction for multiple testing (Table S5).

## 135 **3.1.Phenome-wide-based Mendelian randomisation**

136 We investigated 889 disease outcomes from 18 disease categories in the phenome-wide analyses. We

- 137 observed significant associations between the OC GRS and 10 diseases from four disease categories
- (neoplasms, digestive, respiratory and genitourinary diseases) after FDR correction ( $p \le 5.6 \times 10^{-4}$ ).
- 139 The top signals were for "cancer of the female genital organs", "malignant neoplasm of ovary and
- 140 other uterine adnexa", and "malignant neoplasm of the ovary", which confirms the 'relevance
- 141 assumption' of the MR approach<sup>10</sup> (Supplementary methods) for using the GRS as instrument for OC
- 142 (for all,  $p \le 4.8 \times 10^{-4}$ , Figure 1, Panel A). The GRS was also associated with higher risk of other
- 143 cancers and abnormal growths including "secondary malignant neoplasm of digestive systems",
- 144 "lipoma, including lipoma of skin and subcutaneous tissue" ( $p \le 3.9 \times 10^{-4}$ ), and "ovarian cyst" (p =6.0
- $145 \times 10^{-5}$ ). In addition, we identified associations with respiratory outcomes including "chronic airway"
- 146 obstruction" and "abnormal findings on examination of the lungs", and with the digestive system
- 147 outcome, "ascites" ( $p \le 3.2 \times 10^{-4}$ ).
- 148 In analyses using GRSs for specific OC subtypes (Figure 1 Panel B and C), the clear cell OC GRS
- 149 was associated with additional diseases and increased risks such as "benign neoplasm of uterus", and
- 150 "uterine leiomyoma", "disorders of menstruation", "gram negative septicemia", and "postoperative
- 151 infection" (for all,  $p \le 2.3 \times 10^{-4}$ ). Overall, in addition to overall OC-related outcomes, 12 other
- 152 disease outcomes were associated with at least one form of the OC GRS. Notably, none of these
- 153 associations were detected when we repeated the phenome-wide analyses among men (Figure S4).

154 Additionally, our phenome-wide analyses on 43 quantitative traits, which included serum and urine

155 biomarkers and physiological measures, identified an association of OC GRS with 13 traits.

156 Furthermore, we found an additional 11 traits associated with at least one subtype of OC GRS (Figure 157 S5).

158 We conducted two-sample MR analyses on 12 disease outcomes identified in the PheWAS. For each 159 outcome, evidence of causality was identified for at least one type of OC (Figure 2). We found robust 160 evidence supporting the association between a higher genetic liability of OC and an increased risk of 161 "secondary malignant neoplasm of digestive systems" (OR 1.64, 95% CI 1.33, 2.023), "ascites" (1.48, 162 95% CI 1.17, 1.86), "chronic airway obstruction" (1.17, 95% CI 1.07, 1.29), and "abnormal finding 163 on the examination of the lungs" (1.51, 95% CI 1.22, 1.87). These associations were further supported 164 by other MR methods (Figure S6). Additionally, we observed an association between a higher genetic 165 liability of OC and an increased risk of "ovarian cyst" (1.23, 95% CI 1.04, 1.46), as well as "lipoma 166 including lipoma of skin and subcutaneous tissues" (1.31, 95% CI 1.06, 1.61). Notably, the weighted 167 median and weighted mode MR methods specifically supported the association with "lipoma of the 168 skin and subcutaneous tissues" (Figure S6). There was some evidence supporting the association 169 between OC and higher risk of "postoperative infection" and "gram-negative septicemia", identified 170 in the phenome-wide analyses on clear cell OC. However, these associations were observed only in 171 the IVW and MR-PRESSO MR methods (Figure S6). In the MR analyses on OC subtypes (Figure 2), 172 serous, endometrioid and clear cell OC were all associated with "secondary malignant neoplasm of 173 digestive systems" and "ascites". Serous and endometrioid subtypes showed evidence of effects on 174 the respiratory outcomes. While the case numbers were lower for mucinous OC, this histotype was the 175 only one to show evidence of an association with "lipoma of the skin and subcutaneous tissues" as 176 evidenced by all MR methods. However, mucinous OC was not associated with any of the other 177 outcomes (Figure S6). The clear cell subtype was associated with "ovarian cyst", "benign uterine 178 neoplasms", "uterine leiomyoma", and "disorders of menstruation". Both serous and clear cell 179 subtypes increased the risk of postoperative infection traits, with clear cell also increasing risk for 180 "gram negative septicemia" (Figure 2 & Figure S6). We conducted analyses also excluding all known

181 OC cases, and associations with "secondary malignant neoplasm of digestive systems" and "ascites" 182 were attenuated, while estimates for all other outcomes were generally similar to the main findings 183 (Figure S7). The MR-Egger intercept did not suggest evidence of pleiotropy for most associations, 184 except for the association between serous OC and "postoperative infections" ( $p_{intercept} = 0.01$ ), which 185 therefore should be cautiously interpreted. No evidence of pleiotropy was found using the MR-186 PRESSO outlier test and leave-one-out analysis (Figure S8). The estimates obtained from leave-187 block-out analyses were broadly consistent with the overall findings (Figure S9). 188 MR analyses on serum biomarkers and physiological measures supported the association of 189 OC with lower FVC, endometrioid OC with lower oestradiol, clear cell OC with lower total 190 cholesterol, low density lipoprotein (LDL) cholesterol, and apolipoprotein B (ApoB), and mucinous 191 OC with higher gamma glutamyltransferase (GGT) and alanine aminotransferase (ALT) and lower 192 creatinine levels (Figure S10). Analyses excluding all known OC cases, provided generally similar 193 estimates to the main findings (Figure S11). For these identified associations, we did not find any 194 evidence of pleiotropy based on the MR-Egger intercept tests (pintercept <sup>≥</sup>0.13) and leave-one-out 195 analyses. MR analyses on men provided evidence for a genetic association between mucinous OC and 196 ALT (Figure S10).

197 **3.2. Shared genetic architecture**

198 In the phenome-wide analyses assessing associations with individua OC risk-associated genetic

199 variant, five variants were associated with at least one of 15 (11 distinct) disease outcomes (all,  $p \le 4.5$ 

 $200 \times 10^{-8}$ , Figure 3, Table S6), and seven variants were associated with at least one of 22 biomarkers and

201 physiological measures (Figure S12). Some of these associations were also observed in the analyses

202 among men, with selected OC variants affecting conditions of the male genital organs (Figure 3,

203 Table S6 and Figure S12, Supplementary Results). To ensure the novelty of our findings, we

204 extensively checked the GWAS Catalog for any reports of associations with the identified (or related)

205 diseases involving the lead or proxy variants ( $r^2 \ge 0.1$ ). As a result, we uncovered potential novel

206 associations between the OC risk-increasing allele from the *TERT* locus (rs10069690-T) and a lower

207 risk of "seborrheic keratosis" (0.79, 95% CI 0.72, 0.87), in females, with similar a finding observed in

- 208 males. To further validate the associations, we conducted colocalisation analysis at the *TERT* locus
- 209 (LD block of chr5:982252 to chr5:2132442, human genomic build of hg19) and identified rs4449583
- 210 as the candidate causal variant explaining around 70% of 0.9239 PPFC for OC-"seborrheic keratosis"
- 211 (Figure 4). This variant is also strongly associated with OC in the Phelan OC GWAS<sup>15</sup> (p = 7.8  $\times$ 10<sup>-12</sup>),
- 212 and in LD with the index variant from this GWAS (rs7705526,  $r^2 = 0.784$ ) and with the lead variant in
- 213 the primary discovery OC GWAS<sup>22</sup> (rs100699690,  $r^2 = 0.432$ , Supplementary Methods). The
- 214 association between the *GPX6* locus and "disorders of iron metabolism" and "celiac disease" are
- 215 potentially novel, although colocalisation analysis did not suggest that OC share the same causal
- 216 variants with these two diseases (Figure S13). On the contrary, we identified independent potential
- 217 causal genetic variant for each "disorders of iron metabolism" (rs34409925,  $r^2 = 0.207$  with
- 218 rs6456822) and "celiac disease" (rs3131101,  $r^2 = 0.049$  with rs6456822) in further conditional analysis
- 219 (Figure S13).

## 221 **4. Discussion**



246 evidence for this association, specifically linking OC to an increased risk of "chronic airway

247 obstruction" and "abnormal lung examinations". The findings were further supported by spirometry 248 measures, which showed a significant association between a higher genetic liability to OC and lower 249 FVC. While in women with OC lowering of lung function may follow from malignant pleural 250 effusion and tumour metastasis to the pleura<sup>37</sup> or complications related to surgical procedures,  $^{38}$  in our 251 analysis the association with lung disease remained when OC cases were excluded, and the 252 spirometric association was seen both in women and in men, which may indicate a more profound 253 biological link. 254 OC as reflected by our genetic study arises from the epithelium of the ovaries, endometrium and 255 fallopian tubes, and while most of the lung also consists of epithelium, a direct link has not been well 256 established. Interestingly, colocalisation analyses in our study also suggested that disorder of skin 257 condition (seborrheic keratosis) shared a genetic locus (*TERT*, encoding the enzyme, telomerase) with 258 OC, highlighting potential shared pathomechanisms involving the epithelium, and implicating 259 telomerase function in the opposing risks of OC and the skin disorder.<sup>39, 40</sup> 260 Debulking cytoreductive surgery is the standard procedure for advanced OC. It involves the surgical 261 removal of female reproductive organs such as the ovaries, fallopian tubes, uterus, as well as 262 omentum and organs of the digestive system, such as the bowel, depending on the stage of  $OC^{41}$ . The 263 invasive nature of this intervention, $41$  combined with compromised immune system function resulting 264 from the disease, $42 \text{ may explain the observed association between OC and "postoperative infection"}$ 265 and "gram-negative septicemia". It is important to note that these associations were predominantly 266 observed in clear cell OC, which has also been associated with "benign neoplasms of the uterus", 267 "uterine leiomyoma", and "disorders of menstruation". The presence of these conditions, which 268 primarily involve the uterine tissue, could reflect the well-established association between 269 endometriosis and clear cell OC.<sup>43, 44</sup> Our study also identified OC subtype specific associations 270 between mucinous OC and "lipoma of the skin and subcutaneous tissue". Regarding the biomarkers, 271 endometroid OC was associated with lower serum oestradiol level, clear cell OC was associated with 272 lower serum total cholesterol, LDL cholesterol, and ApoB, while mucinous OC was associated with 273 higher serum GGT and ALT as well as lower creatinine levels. These findings suggests that

274 comorbidities and selected biomarkers may play a role in identifying and characterising different

275 subtypes of OC.



298 Our study has a number of strengths. Firstly, it is the largest (n =181,203) and most comprehensive 299 study to date that examines the health risks associated with a higher genetic susceptibility to OC.

300 Secondly, by including OC subtypes in our analysis, our study can identify subtype-specific 301 comorbidities, supporting more effective treatment and management. Lastly, our study extended the 302 phenome-wide analyses to each OC-risk-increasing variant. This approach enables us to confirm 303 previously identified variant-disease associations and also identify potential novel associations, thus 304 providing a more comprehensive understanding of the shared genetic links between OC and other 305 diseases. Further incorporation of colocalisation analysis is another strength of this study. It provided 306 evidence of a shared genetic locus (*TERT*) between OC and "seborrheic keratosis", and identified a 307 potential novel causal variant, rs4449583, for this skin condition. 308 Our study also has some limitations. To ensure the validity of MR, the genetic instrument used must

309 be associated with the risk factor (in our case, OC), not associated with the confounders of the risk 310 factor-outcome association, and not influence the outcome except through its association with the risk 311 factor. While we used a genetic instrument that associates with OC and conducted our analysis on a 312 white-European population while adjusting for confounding factors, we cannot rule out the absence of 313 horizontal pleiotropic effects, which will affect interpretation and can bias the MR estimates.<sup>56</sup> To 314 address this concern, we repeated our analysis in men to further verify whether the association we 315 observed is genuinely related to OC or a reflection of genetic variants indicating shared mechanistic 316 pathways between both men and women. Another potential limitation of our study is that the UK  $317$  Biobank participants are relatively healthy compared to the general population,<sup>57</sup> introducing to 318 collider bias due to the "healthy volunteer" selection bias.<sup>58</sup> However, the modest collider bias in the 319 context of MR is less likely to affect MR results significantly when the selection into the study was 320 not strongly influenced by the risk factor.<sup>58</sup> Furthermore, the presence of biologically plausible causal 321 associations in our study provides support for the validity of our results despite this limitation. It could 322 be noted as a limitation of our study that our investigation into comorbidities associated with OC was 323 primarily conducted in a population predominantly not diagnosed with OC. However, sensitivity 324 analyses excluding all known OC cases confirmed that the associations with OC complications 325 relating to ascites and gastrointestinal metastases are related to the disease *per se*, while the other

- 326 observed disease and trait associations may reflect earlier stages of OC development or other
- 327 underlying biological differences.
- 328 In conclusion, our study identified robust associations between OC and comorbidities related to the
- 329 digestive and respiratory systems. Furthermore, we observed specific robust associations for different
- 330 subtypes of OC, such as "gram-negative septicemia", 'uterine leiomyoma" and "disorders of
- 331 menstruation" for clear cell OC, and lipoma for mucinous OC. Interestingly, our study points to a
- 332 shared genetic architecture between OC and a skin condition, leading to a discovery of a novel variant
- 333 which merits further investigation.



## 358 **Data availability**

- 359 This research has been conducted using the UK Biobank Resource under Application Number 89630.
- 360 The data and analytical code that support the findings of this study are available on application to the
- 361 UK Biobank (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access).

# 363 **References**



It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.08.23295233;](https://doi.org/10.1101/2023.09.08.23295233) this version posted September 8, 2023. The copyright holder for this preprint

410 16. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-411 Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dörk T, Goode EL, et al. A genome-412 wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat 413 Genet 2009;41:996-1000. 414 17. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, 415 Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, et al. A 416 genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 417 8q24. Nat Genet 2010;42:874-9. 418 18. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-419 Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, et al. Common variants at 19p13 are 420 associated with susceptibility to ovarian cancer. Nat Genet 2010;42:880-4. 421 19. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, 422 Besenbacher S, Lundin P, Stacey SN, Gudmundsson J, Magnusson OT, le Roux L, et al. 423 Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 2011;43:1104-7. 424 20. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy 425 P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, et al. Genome-wide 426 association study in BRCA1 mutation carriers identifies novel loci associated with breast and 427 ovarian cancer risk. PLoS genetics 2013;9:e1003212. 428 21. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley 429 M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, et al. GWAS meta-analysis and 430 replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013;45:362- 431 70, 70e1-2. 432 22. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson 433 K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, et al. Identification of six new 434 susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 2015;47:164-71. 435 23. Kelemen LE, Lawrenson K, Tyrer J, Li Q, Lee JM, Seo JH, Phelan CM, Beesley 436 J, Chen X, Spindler TJ, Aben KK, Anton-Culver H, et al. Genome-wide significant risk 437 associations for mucinous ovarian carcinoma. Nat Genet 2015;47:888-97. 438 24. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, 439 Vukcevic D, Delaneau O, O'Connell J, Cortes A, Welsh S, et al. The UK Biobank resource 440 with deep phenotyping and genomic data. Nature 2018;562:203-09. 441 25. Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools 442 for phenome-wide association studies in the R environment. Bioinformatics 2014;30:2375- 76. 443 444 26. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A 445 framework for the investigation of pleiotropy in two-sample summary data Mendelian 446 randomization. Stat Med 2017;36:1783-802. 447 27. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in 448 mendelian randomization with some invalid instruments using a weighted median estimator. 449 Genet Epidemiol 2016;40:304-14. 450 28. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data 451 Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol 452 2017;46:1985-98. 453 29. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal 454 pleiotropy in causal relationships inferred from Mendelian randomization between complex 455 traits and diseases. Nat Genet 2018;50:693-98. 456 30. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson 457 JR. Assessing the suitability of summary data for two-sample Mendelian randomization 458 analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol

459 2016;45:1961-74.



It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.09.08.23295233;](https://doi.org/10.1101/2023.09.08.23295233) this version posted September 8, 2023. The copyright holder for this preprint

510 association and Mendelian randomisation analysis provide insights into the pathogenesis of 511 heart failure. Nature communications 2020;11:163. 512 49. Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, Narita A, 513 Konuma T, Yamamoto K, Akiyama M, Ishigaki K, Suzuki A, et al. A cross-population atlas 514 of genetic associations for 220 human phenotypes. Nat Genet 2021;53:1415-24. 515 50. Klarin D, Damrauer SM, Cho K, Sun YV, Teslovich TM, Honerlaw J, Gagnon 516 DR, DuVall SL, Li J, Peloso GM, Chaffin M, Small AM, et al. Genetics of blood lipids 517 among ~300,000 multi-ethnic participants of the Million Veteran Program. Nat Genet 518 2018;50:1514-23. 519 51. Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, 520 Venkataraman GR, Wainberg M, Ollila HM, Kiiskinen T, Havulinna AS, Pirruccello JP, et 521 al. Genetics of 35 blood and urine biomarkers in the UK Biobank. Nat Genet 2021;53:185- 522 94. 523 52. Dev S, Babitt JL. Overview of iron metabolism in health and disease. 524 Hemodialysis international. International Symposium on Home Hemodialysis 2017;21 Suppl 525 1:S6-s20. 526 53. Rafnar T, Gunnarsson B, Stefansson OA, Sulem P, Ingason A, Frigge ML, 527 Stefansdottir L, Sigurdsson JK, Tragante V, Steinthorsdottir V, Styrkarsdottir U, Stacey SN, 528 et al. Variants associating with uterine leiomyoma highlight genetic background shared by 529 various cancers and hormone-related traits. Nature communications 2018;9:3636. 530 54. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, 531 Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, et al. 532 Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility 533 loci. Nat Genet 2018;50:928-36. 534 55. Pendergrass SA, Brown-Gentry K, Dudek SM, Torstenson ES, Ambite JL, Avery 535 CL, Buyske S, Cai C, Fesinmeyer MD, Haiman C, Heiss G, Hindorff LA, et al. The use of 536 phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype 537 relationships and pleiotropy discovery. Genet Epidemiol 2011;35:410-22. 538 56. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid 539 instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 540 2015;44:512-25. 541 57. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, 542 Allen NE. Comparison of sociodemographic and health-related characteristics of UK 543 Biobank participants with those of the general population. Am J Epidemiol 2017;186:1026- 34. 544 545 58. Gkatzionis A, Burgess S. Contextualizing selection bias in Mendelian 546 randomization: how bad is it likely to be? Int J Epidemiol 2019;48:691-701. 547

## 549 **Figure legends**



- 564 Panel A. Stacked regional association plots of ovarian cancer and seborrheic keratosis. Panel B.
- 565 Portions of the Posterior probability for full colocalisation (PPFC) explained by each genetic variant
- 566 at the *TERT* locus. The  $r^2$  colour legends reflect the  $r^2$  of each variant with respect to the lead variant.

# 568 **Tables**



#### 569 **Table 1.** Prevalence of ovarian cancer by population characteristics

 $570$  p is p-value generated from likelihood ratio test in logistic models adjusted for age, birth location and assessment centers. BMI: body mass index.

location and assessment centers. BMI: body mass index.



# **Panel C**



#SNPs

OR (95% CI)



.4 1 2 4





.3

1

# Ovarian cancer







Phenome-wide association study of ovarian cancer identifes common comorbidities and reveals shared genetics with complex diseases and biomarkers

